Women Are Leading The Longevity Movement, Data From Livelong Media Suggests
PALM BEACH, FL - March 20, 2025 ( NEWMEDIAWIRE) - A recent analysis of Livelong Media's audience data uncovered that 84% of its event attendees and 79% of its social media engagement comes from women. The data is undeniable: Women are not just participating in the longevity movement - they are leading it.
Giving Women the Mic: Dr. Vonda Wright Named Official Host of Livelong Experience 2025
In response to this data, Livelong Media is putting female voices front and center, announcing that Dr. Vonda Wright will serve as the host and emcee of the 2025 Livelong Experience in Palm Beach, March 28-29. The trailblazing surgeon, researcher, and longevity advocate has captivated millions with her no-nonsense, science-backed approach to aging. Her recent viral appearances on The Mel Robbins Podcast and Diary of a CEO, where her episodes collectively have garnered over 1 million views in just days, have further cemented her as one of the most influential voices in longevity, among men and women.
Dr. Wright will lead the agenda of powerhouse speakers and an extraordinary roster of female leaders who will share groundbreaking research and lead engaging, transparent discussions about living longer, healthier lives. Speakers include:
- Dr. Megan Hall, VP of Medical Affairs at GRAIL
- Dr. Asima Ahmad, Co-founder and Chief Medical Officer at Carrot Fertility
- Dr. Caitlin Prickett, Founder of Concierge Medicine of Boca Raton
- Aurora Griffin, Managing Partner at LongeVC
- Elizabeth Tringali, Founder of Tringali Vibrant Health
- Dahlia Attia-King, Founder of Pancea
- Kimberly Hand, Host of The Cinnamon Effect podcast
- Ella Davar, Founder of The Gut-Brain Method
- Amber Berger, Founder of The Well Drop
- Shebah Carfagna, Founder of Panache Fitness
Longevity for Everyone While Giving a Voice to Women
'The longevity movement is deeply personal to women,' said Livelong Media founder and renowned journalist, Brad Inman. 'They are leading this conversation, and so we are making sure their voices are not just heard, but amplified.' The Livelong Experience is not pivoting to a women's health conference. It is making a bold statement in response to the overwhelming data. Despite men historically dominating the stage as speakers and experts, women are the ones showing up in record numbers, demanding science-backed insights, real conversations, and representation in the longevity movement.
Now Available via Live Stream
For those unable to attend in person, The Livelong Experience will be available via live stream, ensuring that women and men from around the world can participate in the longevity movement. To purchase tickets to attend The Livelong Experience in person and for live-stream information, visit www.livelong.events.
About
Livelong Media is an independent media company and news platform dedicated to making longevity science accessible, transparent, and actionable. Founded by award-winning journalist and entrepreneur Brad Inman, Livelong Media applies the same investigative rigor that defined Inman News in the real estate industry, to the health and wellness space. With longevity breakthroughs emerging at a rapid pace, consumers are often left navigating conflicting advice, marketing-driven claims, and inaccessible expertise. Livelong Media was created to bridge this gap, bringing together trusted experts, verified research, and real-world solutions through live events, digital media, and a growing community.
The Livelong Experience gathers leading doctors, scientists, and health innovators for unfiltered discussions and science-backed insights. Livelong Media is committed to elevating diverse voices in the longevity movement, ensuring that everyone, not just industry insiders, can access the latest advancements in health, wellness, and aging. For more information, visit https://www.livelong.events.
Media Contact
Holly Meyer Lucas
Principal
Hype Boss
1(561) 631- 0381
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 hours ago
- Associated Press
Screening for cardiovascular disease marker in community health centers may reduce risk
( NewMediaWire ) - July 23, 2025 - DALLAS — Elevated lipoprotein(a), also known as Lp(a), is an independent, inherited and causal risk factor for cardiovascular disease, the leading cause of death and disability worldwide. [1] Lp(a) is similar to low-density lipoprotein (LDL), or 'bad' cholesterol, yet is caused by genetics and is not impacted by lifestyle modifications. While it is estimated that 1 in 5 Americans have high Lp(a) levels, many people are not aware of their risk. Research has found less than 1% of people with atherosclerotic cardiovascular disease (ASCVD), which is caused by plaque buildup in the arteries, are tested for Lp(a). [2] The American Heart Association, a global force changing the future of health for all, has launched the Lp(a) Community Health Centers Discovery Project, supported by Novartis Pharmaceuticals Corporation, to increase awareness about Lp(a). Additionally, the initiative will focus on improving shared decision making between health care professionals and individuals within community health centers (CHCs) on the importance of Lp(a) screening and ASCVD risk management. 'A simple, one-time Lp(a) test can give lifelong insight about overall heart disease risk — especially for people with a family history or who are otherwise at increased risk,' said Kaavya Paruchuri, M.D., American Heart Association volunteer and clinical operations director of the cardiovascular medicine section and director of the Lipid Apheresis Unit, Preventive Cardiology, at Massachusetts General Hospital in Boston. 'Community health centers are vital for making this important tool available to more people and helping individuals take control of their heart health.' Ten CHCs throughout the U.S. signed onto the project in 2024, and 10 additional sites will be added this year. So far, participating CHCs have successfully added new Lp(a) screening processes resulting in increased testing at the sites. This reflects strong momentum for expanding Lp(a) testing access. Current participating CHCs include: In 2023, the American Heart Association launched an initiative called the Lp(a) Discovery Project to improve the number of patients screened for Lp(a) through professional and patient education. This initiative gathered insights from 10 health systems across the country who have established Lp(a) testing processes. Lessons learned from this initiative will be used to drive improvements across CHCs participating in the Lp(a) Discovery Community Health Centers Project. Studies have shown that elevated Lp(a) increases risk for ASCVD-related events such as aortic stenosis, heart attack, peripheral artery disease and stroke. [3] Although treatment options for high Lp(a) are limited, some lifestyle changes and medication therapies can assist with lowering a person's overall risk for heart disease. A baseline survey conducted as part of the Lp(a) Discovery Project found few U.S. adults are aware of Lp(a), which is accompanied by lack of concern and urgency to have levels checked. U.S. adults are not linking elevated Lp(a) to cardiovascular risk, but when they do, it motivates them to talk to their doctor. Health care professionals are the top source of Lp(a) awareness; their recommendation and personal experience is key to considering getting Lp(a) levels checked. Community Health Centers can express interest in participating in this initiative by completing the form at The deadline is August 15. Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Michelle Rosenfeld: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and [1] Reyes-Soffer G, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. October 14, 2021. 42(1). [2] Shah N, Mulder H, et al. Lipoprotein (a) Testing in Patients With Atherosclerotic Cardiovascular Disease in 5 Large US Health Systems. JAHA. November 4, 2024. 13(21). [3] Wilson D, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Journal of Clinical Lipidology. 2019. Tsimikas S, Marcovina S. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. JACC. August 2022. 80(9):934–946.
Associated Press
16-07-2025
- Associated Press
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
By Meg Flippin Benzinga DETROIT, MICHIGAN - July 16, 2025 ( NEWMEDIAWIRE ) - Lance Alstodt, CEO of BioRestorative Therapies (NASDAQ: BRTX), was recently a guest on Benzinga's All-Access. BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to achieve those goals. The company's flagship product candidate, BRTX-100, just completed a phase 2 clinical trial for chronic lumbar disc disease (cLDD), which Alstodt was on hand to discuss with Benzinga. 'Data from the first 36 patients was highly encouraging,' Alstodt told Benzinga in the interview. 'At 52 weeks over 74% of participants demonstrated greater than 50% improvement in function and over 72% reported a greater than 50% reduction in pain, both substantially exceeding the FDA's clinically meaningful threshold of 30%,' Alstodt said the phase 2 outcome set the stage for a pivotal trial or even accelerated path to approval. BRTX-100 is an autologous stem cell product for chronic lower back pain. It uses a patient's stem cells, which are harvested, cultured and then injected directly into the affected disc to start the repair process. During the interview, Alstodt told Benzinga that he thinks what makes BRTX-100 different is that instead of masking the pain, like opioids and injectables, the BioRestorative product candidate is targeting the root cause. The goal of the phase 2 trials is to enroll a total of 99 patients, which the CEO said is tracking well. An announcement on that front is expected soon. But that's not all Alstodt revealed in this wide-ranging interview. From BioRestorative's expansion plans to what's next for the company, the executive had a lot to share in this must-watch All Access interview. Watch the full interview here: Featured image fromShutterstock. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.
Associated Press
16-07-2025
- Associated Press
Adults with heart-healthy metrics had better health from head to toe
Research Highlights: Embargoed until 4 a.m. CT/5 a.m. ET, Wednesday, July 16, 2025 ( NewMediaWire ) - July 16, 2025 - DALLAS — People who had more heart-healthy habits and factors, as assessed by the American Heart Association's Life's Simple 7(TM) metrics for ideal cardiovascular health, had more positive benefits for whole body health, according to a review of research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association. Life's Simple 7 was launched by the American Heart Association in 2010 to define and quantify the spectrum of heart health based on seven lifestyle and health measures: not smoking, healthy nutrition, regular physical activity, healthy weight and normal blood pressure, cholesterol and blood sugar levels. In 2022, the metrics were refined to include sufficient sleep and more detailed scoring. The updated cardiovascular health metric is now called Life's Essential 8(TM). While the cardiovascular benefits of optimal cardiovascular health in terms of Life's Simple 7 were already well-established, this is the first systematic review that examines the benefits to organs beyond the heart and death from cardiovascular disease and other causes, according to study authors. 'A few years ago, we learned that heart health and brain health are very closely tied. Through this review, we found that almost every organ system and bodily function also benefits from maintaining the healthy lifestyle behaviors of Life's Simple 7,' said lead study author Liliana Aguayo, Ph.D., M.P.H., a research assistant professor at the Nell Hodgson Woodruff School of Nursing and the Global Diabetes Research Center at Emory University in Atlanta. 'We were pleasantly surprised to find that Life's Simple 7 at optimal levels touched every aspect of health, from head to toe. It goes well beyond just cardiovascular health to encompass whole-body health.' Researchers reviewed nearly 500 research studies published in the decade after Life's Simple 7 was introduced that had incorporated at least three of Life's Simple 7 measures. Ideal cardiovascular health was defined as having six or seven of the metrics at high levels. Among the findings: 'These findings confirm that healthy lifestyle metrics — eating well, exercising and not smoking — are key components to optimal health, in addition to maintaining healthy weight, normal blood pressure, and cholesterol blood sugar levels, which are the conventional risk factors for cardiovascular disease,' Aguayo said. 'The ideal cardiovascular health metrics in Life's Simple 7 and now Life's Essential 8 are based on extensive scientific research that recognizes the majority of heart disease and stroke can be prevented,' said Stacey E. Rosen, M.D., FAHA, volunteer president of the American Heart Association and senior vice president of women's health and executive director of the Katz Institute for Women's Health of Northwell Health in New York City. 'The findings in this review study indicate that these healthy lifestyle metrics are also a path to improving health and well-being across the board, from head to toe. Preventing cardiovascular disease and reducing cardiovascular disease risk, the centerpieces for Life's Essential 8, are the core of the American Heart Association's mission to be a relentless force for a world of longer, healthier lives.' The review findings are limited due to the scoring system of Life's Simple 7, which rates each category broadly as ideal, intermediate or poor and is less precise than is now possible under the methods of Life's Essential 8, according to Aguayo. Because this study relies on published literature, it may under-represent studies with negative or inconclusive findings, researchers said. The investigators called for more research especially among children, pregnant women and populations in less-studied areas of the world. Also, more research is needed on both the benefits of even small improvements in these health metrics and the mechanisms that are pathways between Life's Simple 7 or Life's Essential 8 and better health. Study details, background and design: This review was partially funded by a Strategically Focused Research Network grant from the American Heart Association as well as a grant from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association. Co-authors and disclosures are listed in the manuscript. Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content. Overall financial information is available here. Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173 Staff contact: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
